CHAPTER 1: INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies

3.3. MARKET SHARE ANALYSIS
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in Prevalence of Depression
3.5.1.2. Rise in Geriatric Population
3.5.1.3. Increase in Awareness

3.5.2. Restrains

3.5.2.1. Non-Pharmacological Therapies Preferred Over Pharmacological Therapies
3.5.2.2. Poor Efficacy and Safety Profiles
3.5.2.3. Patent Expiry of Antidepressants leading to Weak Pipeline

3.5.3. Opportunities

3.5.3.1. Emergence of Novel Multimodal Therapies

CHAPTER 4: ANTI-DEPRESSANT DRUGS MARKET BY DEPRESSIVE DISORDER

4.1. OVERVIEW

4.1.1. Market Size and Forecast

4.2. MAJOR DEPRESSIVE DISORDER

4.2.1. Key Market Trends & Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country

4.3. OBSESSIVE-COMPULSIVE DISORDER

4.3.1. Key Market Trends & Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country

4.4. GENERALIZED ANXIETY DISORDER

4.4.1. Key Market Trends & Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country

4.5. PANIC DISORDER

4.5.1. Key Market Trends & Opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country

4.6. OTHERS

4.6.1. Key Market Trends & Opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country

CHAPTER 5: ANTI-DEPRESSANT DRUGS MARKET BY PRODUCT TYPE

5.1. OVERVIEW

5.1.1. Market Size and Forecast

5.2. TRICYCLIC ANTIDEPRESSANTS

5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country

5.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS

5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country

5.4. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS

5.4.1. Market Size and Forecast
5.4.2. Market Analysis, by Country

5.5. MONOAMINE OXIDASE INHIBITORS

5.5.1. Market Size and Forecast
5.5.2. Market Analysis, by Country

5.6. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS

5.6.1. Market Size and Forecast
5.6.2. Market Analysis, by Country

5.7. OTHERS

5.7.1. Market Size and Forecast
5.7.2. Market Analysis, by Country

CHAPTER 6: ANTI-DEPRESSANT DRUGS MARKET BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market Size and Forecast

6.2. NORTH AMERICA

6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Depressive Disorder
6.2.3. Market Size and Forecast, by product type
6.2.4. Market Analysis, by Country

6.2.4.1. U.S. Market Size and Forecast, by Depressive Disorder
6.2.4.2. U.S. Market Size and Forecast, by product type
6.2.4.3. Canada Market Size and Forecast, by Depressive Disorder
6.2.4.4. Canada Market Size and Forecast, by Product Type
6.2.4.5. Mexico Market Size and Forecast, by Depressive Disorder
6.2.4.6. Mexico Market Size and Forecast, by Product Type

6.3. EUROPE

6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Depressive Disorder
6.3.3. Market Size and Forecast, by Product Type
6.3.4. Market Analysis, by Country

6.3.4.1. Germany Market Size and Forecast, by Depressive Disorder
6.3.4.2. Germany Market Size and Forecast, by Product Type
6.3.4.3. France Market Size and Forecast, by Depressive Disorder
6.3.4.4. France Market Size and Forecast, by Product Type
6.3.4.5. UK Market Size and Forecast, by Depressive Disorder
6.3.4.6. UK Market Size and Forecast, by Product Type
6.3.4.7. Italy Market Size and Forecast, by Depressive Disorder
6.3.4.8. Italy Market Size and Forecast, by Product Type
6.3.4.9. Spain Market Size and Forecast, by Depressive Disorder
6.3.4.10. Spain Market Size and Forecast, by Product Type
6.3.4.11. Rest of Europe Market Size and Forecast, by Depressive Disorder
6.3.4.12. Rest of Europe Market Size and Forecast, by Product Type

6.4. ASIA-PACIFIC

6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Depressive Disorder
6.4.3. Market Size and Forecast, by Product Type
6.4.4. Market Analysis, by Country

6.4.4.1. Japan Market Size and Forecast, by Depressive Disorder
6.4.4.2. Japan Market Size and Forecast, by Product Type
6.4.4.3. China Market Size and Forecast, by Depressive Disorder
6.4.4.4. China Market Size and Forecast, by Product Type
6.4.4.5. Australia Market Size and Forecast, by Depressive Disorder
6.4.4.6. Australia Market Size and Forecast, by Product Type
6.4.4.7. India Market Size and Forecast, by Depressive Disorder
6.4.4.8. India Market Size and Forecast, by Product Type
6.4.4.9. South Korea Market Size and Forecast, by Depressive Disorder
6.4.4.10. South Korea Market Size and Forecast, by Product Type
6.4.4.11. Rest of Asia-Pacific Market Size and Forecast, by Depressive Disorder
6.4.4.12. Rest of Asia-Pacific Market Size and Forecast, by Product Type

6.5. LAMEA

6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Depressive Disorder
6.5.3. Market Size and Forecast, by Product Type
6.5.4. Market Analysis, by Country

6.5.4.1. Brazil Market Size and Forecast, by Depressive Disorder
6.5.4.2. Brazil Market Size and Forecast, by Product Type
6.5.4.3. Saudi Arabia Market Size and Forecast, by Depressive Disorder
6.5.4.4. Saudi Arabia Market Size and Forecast, by Product Type
6.5.4.5. South Africa Market Size and Forecast, by Depressive Disorder
6.5.4.6. South Africa Market Size and Forecast, by Product Type
6.5.4.7. Rest of LAMEA Market Size and Forecast, by Depressive Disorder
6.5.4.8. Rest of LAMEA Market Size and Forecast, by Product Type

CHAPTER 7: COMPANY PROFILES

7.1. ALKERMES PLC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance

7.2. ALLERGAN PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. BRISTOL MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Business performance

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance

7.5. GLAXOSMITHKLINE INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance

7.6. H. LUNDBECK A/S

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Business performance
7.6.4. Key strategic moves and developments

7.7. MERCK INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance

7.8. PFIZER INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance

7.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance

7.10. TAKEDA PHARMACEUTICAL INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Business performance